Cabaletta Bio

MuSK-CAART Clin1 myasthenia gravis; PLA2R-CAART Clin0 membranous nephropathy; CABA-201 3 efforts Clin0 SLE, undisclosed; DSG3/1-CAART RD mucocutaneous pemphigus vulgaris

Cabaletta Bio is developing T cell therapies for patients with B cell-mediated autoimmune diseases. Engineered T cell therapy takes advantage of T cell’s natural cell-killing capabilities and redirects their specificity to disease-causing cells by inserting a gene encoding a specific receptor. Known as chimeric antigen receptor (CAR) T cells, this approach has shown much success in cancer treatment. Cabaletta is encompassing CAR T cells for Autoimmunity (CARTA) which they hope to apply to many B cell-mediated autoimmune diseases. Cabaletta’s lead candidate in preclinical stages, CABA-201, is a fully human CD19 CARTA approach which has the potential to eliminate disease-causing B cells and allow for healthy B cell repopulation.